TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06338748

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitor (CGM) Dexcom G7 used in blinded mode
Description: Dexcom G7 used in blinded mode
Study: NCT04421573

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BCPHD with D5W
Description: D5W is injected under the investing fascia of the sternocleidomastoid muscle (SCM) using ultrasound guidance in order to infiltrate the space containing the cervical plexus. This is performed on both sides.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Waiting period with usual care
Description: Same as previous group description
Study: NCT05553496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Group (1) RTX in Refractory Nephrotic syndrome patients on conventional treatment (20 patients)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Group (2) Refractory Nephrotic Syndrome patients on Conventional therapy (20 patients)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Group (2) Refractory Nephrotic Syndrome patients on Conventional therapy (20 patients)
Study: NCT04805385

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS128
Description: Each PS128 capsule contained \>1 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PS128
Description: Each PS128 capsule contained \>1 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
Study: NCT06202534

Intervention type: OTHER
Description: radiotherapy

Intervention type: OTHER
Description: radiotherapy

Intervention type: OTHER
Description: radiotherapy

Intervention type: OTHER
Description: radiotherapy
Study: NCT05911919

Intervention type: DEVICE
Intervention: brainQuant module of brainTale-care platform
Description: brainQuant is a software module of brainTale-care medical device (a medical device software as a service (web platform) ) for the automatic processing of brain diffusion Magnetic resonance images and the provision of the diffusion regional standardised parameters.
Study: NCT05816096

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hall technique
Description: The child will be placed to them SSC on one of their HSPM affected teeth. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3_6_9_12 month.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ART
Description: The child will be restored to them one of their HSPM affected teeth by GIC. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3_6_9_12 month.
Study: NCT06019507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCD601
Description: Investigational Product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning Regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC
Description: Immunosuppression Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: Immunosuppression Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Immunosuppression Therapy
Study: NCT06654791

Intervention type: DRUG
Group type: OTHER
Intervention: [14C] SIM0270 Oral Preparation
Description: Use according to the prescribed protocol
Study: NCT04797481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Group A participants will be invited to attend up to 24 exercise sessions (2 sessions per week and a 3rd optional) and 2 virtual (online; a 3rd will be optional) HF workshops over 8 weeks. All sessions will be delivered via online platforms, with 1 facilitator supporting up to 8 participants simultaneously in each session.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self-managed exercise
Description: Group B participants will be provided with a self-care exercise programme. The exercise programme will be home-based with a mixture of online video calls and telephone support contacts, alternating once every other week. The video or telephone contacts will be mutually agreed by the patient and the facilitator at a mutually convenient time and will aim to support Group B participants, by offering advice and tracking progress. Patients will be provided with two exercise programmes: I) a chair-based exercise programme (DVD will be provided), and ii) a progressive walking training programme (a manual will be provided). Patients will be advised to exercise ≥3 times per week, starting from their own personal level and gradually building up over 8 weeks in session's duration, frequency of sessions per week, and walking pace.
Study: NCT04981067

Intervention type: OTHER
Group type: OTHER
Intervention: Maintain the concentration of ropivacaine as same as those used in the previous participant
Description: Maintain the same concentration of ropivacaine used in the previous participant with an 89% chance through a random assignment

Intervention type: OTHER
Group type: OTHER
Intervention: Decrease the ropivacaine concentration by 0.05% from the concentration used in the previous participant
Description: Decrease ropivacaine concentration by 0.05% from the concentration used in the previous participant with an 11% chance through a random assignment

Intervention type: OTHER
Group type: OTHER
Intervention: Increase the ropivacaine concentration by 0.05% from the concentration used in the previous participant
Description: Increase ropivacaine concentration by 0.05% from the concentration used in the previous participant.
Study: NCT06589661

Intervention type: OTHER
Intervention: Interview
Description: Patients will be interviewed by the research team to learn about their experience of Cesarean delivery under general anesthetic.
Study: NCT06605456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation with postural education
Description: Phase 1: Active Rhythmic Initiation The exercise was demonstrated to the students in a seated position, as sitting is considered the functional position for neck motion and stability. Then, the exercises was passively practiced on the students using tactile input. After passive demonstration, students were asked to perform the same exercise actively and verbal commands were used to guide and correct them.~Phase 2: Resisted Rhythmic Initiation Modified The investigators applied resistance by placing the palm of one hand on the right side of the chin to strengthen the muscles. Then, resisted scapular posterior depression PNF exercise also employed.~Also received a comprehensive postural education program to emphasize the importance of proper posture. The program was divided into three sections, which focused on the effects of good and bad posture, as well as practical demonstration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active neck muscle stretching and strengthening exercises
Description: Phase 1: Active Muscle Stretching In this phase, participants were instructed on performing active muscle stretching exercises for all cervical muscles, including neck flexors, extensors, lateral flexors and neck rotators. Each stretch was held for a period of 25-30 seconds and repeated three times.~Phase 2: Self-Isometric Strengthening Participants were provided with a demonstration of self-isometric strengthening exercise for the neck muscles. The exercises involved six movement patterns: cervical flexion, cervical extension, right/left lateral flexion and right/left rotation. For each exercise the participants were required to apply resistance against the direction of movement using their hand without allowing any motion in the neck.~Also received a comprehensive postural education program to emphasize the importance of proper posture. The program was divided into three sections, which focused on the effects of good and bad posture, as well as practical demonstration.
Study: NCT06597760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide
Description: Participants will receive 20 mg enlicitide/180 mg sodium caprate coadministered with 0.25mg Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide
Description: Participants will receive 20 mg enlicitide/180 mg sodium caprate coadministered with 0.25mg Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Participants will receive 0.25 mg digoxin orally on Day 1 Period 1 in Arm A and Day 1 Period 2 in Arm B. They also receive Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B coadministered with oral 20 mg enlicitide/180 mg sodium caprate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Participants will receive 0.25 mg digoxin orally on Day 1 Period 1 in Arm A and Day 1 Period 2 in Arm B. They also receive Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B coadministered with oral 20 mg enlicitide/180 mg sodium caprate.
Study: NCT06002490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101
Description: The subjects will be treated with P1101(ropeginterferon alfa-2b), starting at a dose of 250 micrograms. The dose of P1101 will be increased to 350 micrograms 2 weeks later and to 500 micrograms another 2 weeks later, and then P1101 will be administered at a fixed dose of 500 micrograms throughout the treatment period. Although the dose may be reduced to the prior dose for reasons related to the safety or tolerability, the increased dose should be preferably maintained throughout the treatment period.~The dose of P1101 will be increased or decreased appropriately depending on the pathological condition in the range up to 500 micrograms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Description: Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Phlebotomy is performed aiming at a hematocrit \< 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.
Study: NCT06677567

Intervention type: OTHER
Intervention: Air-Q Intubating Airway
Description: Patients will be inserted Air-Q Intubating Airway under general anesthesia

Intervention type: OTHER
Intervention: proseal laryngeal mask
Description: Patients will be inserted proseal laryngeal mask under general anesthesia.
Study: NCT06676709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMMUNEPOTENT-CRP (I-CRP)
Description: IMMUNEPOTENT-CRP (I-CRP), a bovine dialyzable leukocyte extract (DLE) obtained from disrupted spleen cells, is a mixture of low-molecular-weight peptides (\<12 kDa) that exhibit non-specific immunomodulatory properties.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: The placebo was prepared from a lyophilized corn starch extract and was provided in an identical appearance and presentation to IMMUNEPOTENT-CRP (I-CRP).
Study: NCT06678698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Panel Effective Photobiomodulation Therapy
Description: Photobiomodulation therapy is the use of low-power light in biological tissues through a non-ionizing source of light (600 to 1.100 nm), with variable power between 1 and 500 mW and therapeutic goals.~This group will receive photobiomodulation from a whole-body panel of low intensity LEDs

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Panel Photobiomodulation Therapy
Description: Use of common red lamp to perform the sham photobiomodulation for the panel group

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Modified ILIB Sham Photobiomodulation Therapy
Description: ILIB Therapy device turned off for the sham ILIB therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified ILIB Photobiomodulation Therapy
Description: Common laser used in ILIB mode for modified ILIB therapy
Study: NCT06680336

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mulit-componant neuropsychological assessment
Description: Multi-component cognitive assessment including following domains: attention \& information speed, executive functioning, verbal memory, language, visuospatial-construction and orientation.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mulit-componant neuropsychological assessment
Description: Multi-component cognitive assessment including following domains: attention \& information speed, executive functioning, verbal memory, language, visuospatial-construction and orientation.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Multimodal MRI
Description: Structural MRI (e.g., MPRAGE, DTI) and functional MRI (introducing a modified working memory task for stroke patients)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Multimodal MRI
Description: Structural MRI (e.g., MPRAGE, DTI) and functional MRI (introducing a modified working memory task for stroke patients)
Study: NCT06681675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The group that applied the Intrapartum Care Model
Description: In pregnant women with cervical dilatation of 5 cm, the Personal Information Form was completed at the initial clinic admission.~•The Intrapartum Care Model was implemented for all primiparous pregnant women assigned to the intervention group during labor and after delivery by the researcher midwife, in accordance with the World Health Organization's positive birth recommendations.~Data were collected using the Personal Information Form, Labor and Postpartum Follow-up Form, Visual Analog Scale (VAS), Labor Comfort Scale (CSC), Intrapartum Fear of Labor Scale, and Women's Perception of Supportive Care Given During Labor Scale. VAS, CSC, and Fear of Labor Scale were applied to women when cervical dilation was 5 cm and 9 cm. After delivery, the Women's Perception of Supportive Care Given During Labor Scale was applied.
Study: NCT06681181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4528287
Description: GSK4528287 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4528287
Description: GSK4528287 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4528287
Description: GSK4528287 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4528287
Description: GSK4528287 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4528287
Description: GSK4528287 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4528287
Description: GSK4528287 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT06680258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPST-1120
Description: TPST-1120 is an orally administered competitive antagonist of peroxisome proliferator-activated receptor α (PPARα)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is an IV administered biologic.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab is an IV administered biologic.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is an IV administered biologic.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is an IV administered biologic.
Study: NCT06681701

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Manual Therapy and Pulmonary Exercises
Description: Diaphragmatic breathing exercise:~Segmental breathing exercises (apical, upper lateral, lower lateral and posterior basal), according to site of consolidation:~Active Cycle Breathing Technique (ACBT):~Intensive spirometry: It encourages patients to take deep breaths, which helps to expand the lungs and prevent complications such as pneumonia.~Rib mobilization from sitting:~Rib mobilization from supine:~Central Posterior-Anterior (PA) mobilization of thoracic facet joints:~Unilateral Posterior-Anterior mobilization of costo-vertebral joints:~Diaphragmatic myofascial release (DMR):~Pectoralis minor myofascial release:~Pectoralis major and pectoral fascia myofascial release:~Sternocleidomastoid myofascial release:~Scalene muscle and neck fascia myofascial release:~Mobilize one side of the chest:

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Manual Therapy and Pulmonary Exercises
Description: Diaphragmatic breathing exercise:~Segmental breathing exercises (apical, upper lateral, lower lateral and posterior basal), according to site of consolidation:~Active Cycle Breathing Technique (ACBT):~Intensive spirometry: It encourages patients to take deep breaths, which helps to expand the lungs and prevent complications such as pneumonia.~Rib mobilization from sitting:~Rib mobilization from supine:~Central Posterior-Anterior (PA) mobilization of thoracic facet joints:~Unilateral Posterior-Anterior mobilization of costo-vertebral joints:~Diaphragmatic myofascial release (DMR):~Pectoralis minor myofascial release:~Pectoralis major and pectoral fascia myofascial release:~Sternocleidomastoid myofascial release:~Scalene muscle and neck fascia myofascial release:~Mobilize one side of the chest:
Study: NCT06686056

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AIM-CHD Mobile Health Intervention
Description: The AIM-CHD platform synchronizes data from hospitalization records, questionnaires, AI-powered voice follow-ups, and wearable devices to perform risk stratification and manage uncontrolled risk factors. It provides individualized follow-up plans, medication reminders, and lifestyle education, with real-time assessments of vital health metrics to prompt necessary in-person consultations. The app offers online consultation access and emergency services through Fuwai Hospital. Additionally, it delivers personalized patient education, aligning with the latest clinical guidelines.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Usual post-discharge care
Description: Usual post-discharge care includes oral and written instructions on sustained pharmacotherapy regimens, recommended follow-up frequency, and lifestyle modifications.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Usual post-discharge care
Description: Usual post-discharge care includes oral and written instructions on sustained pharmacotherapy regimens, recommended follow-up frequency, and lifestyle modifications.
Study: NCT06703697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eDrugSafe
Description: The eDrugSafe mobile web platform enables management of medication history and provides electronic access to medicinal product information (ePI). QR codes are separately provided for prescription records to facilitate direct access to ePI.
Study: NCT06614361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led shared decision-making
Description: 1 session and FU calls with a trained nurse

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led shared decision-making
Description: 1 session and FU calls with a trained nurse

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led shared decision-making
Description: 1 session and FU calls with a trained nurse

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led shared decision-making
Description: 1 session and FU calls with a trained nurse

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led shared decision-making
Description: 1 session and FU calls with a trained nurse

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Health \&amp; wellness interactive text message (TM) intervention (12 weeks, 2 texts/week)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Health \&amp; wellness interactive text message (TM) intervention (12 weeks, 2 texts/week)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Health \&amp; wellness interactive text message (TM) intervention (12 weeks, 2 texts/week)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Health \&amp; wellness interactive text message (TM) intervention (12 weeks, 2 texts/week)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Health \&amp; wellness interactive text message (TM) intervention (12 weeks, 2 texts/week)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Health \&amp; wellness interactive text message (TM) intervention (12 weeks, 2 texts/week)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Health \&amp; wellness interactive text message (TM) intervention (12 weeks, 2 texts/week)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Health \&amp; wellness interactive text message (TM) intervention (12 weeks, 2 texts/week)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery prize for vaccination
Description: Modest lottery prize for COVID vaccination
Study: NCT05292287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polar Ignite Wearable Activity Monitor
Description: A wearable activity monitor capable of monitoring outcomes relating to physical activity sedentary time, heart rate, and sleep quality. The watch synchronises to a corresponding mobile app called Polar Flow- Sync and Analyze or to the Polar FlowSync data transfer software on a computer.